Therapeutic Indications

Conferences & Courses
Immunomodulatory Therapeutic Antibodies for Cancer Immunomodulatory Therapeutic Antibodies for Cancer
August 11-12, 2014 | Boston, MA
The Clinical Genome Conference, June 10-12, 2014 The unstoppable march of genomics into clinical practice continues.

Combination Cancer Immunotherapy Combination Cancer Immunotherapy
August 12-13, 2014 | Boston, MA
The Clinical Genome Conference, June 10-12, 2014 The unstoppable march of genomics into clinical practice continues.

Predictive Cancer Biomarkers Predictive Cancer Biomarkers
August 19-20, 2014 | Washington, DC
The Sixth Annual Next Generation Dx Summit (Enabling Point-of-Care Diagnostics, Cancer Molecular Markers to Guide Therapy, Molecular Detection of Infectious Disease and Pathogens, Companion Diagnostics, Commercialization of Molecular Diagnostics, Inherite




Life Science Media Library
Understanding EMT: Mechanisms and Metastasis to MET Understanding EMT: Mechanisms and Metastasis to MET
February 20, 2012 |
Epethelial Mesenchymal Transition (EMT) plays a critical role in cancer cells, but understanding of its mechanisms is incomplete. EMT causes cells to develop increased motility, invasiveness, and greater resistance to apoptosis. These changes make the cells more like stem cells, allowing them to self renew. This course provides a framework of the underlying molecular mechanisms while addressing stem cells, and cancer progression, cMET and their activity as anti-metastasis agents, and the Mesenchymal-Epethelial Transition (MET) as an essential process for tumor re-initiation, colonization, and metastasis.
CTCs from Bench to Bed CTCs from Bench to Bed
February 20, 2012 |
This course will focus on validation of CTC research data for clinical practice, correlations between CTCs, diagnosis and responses to therapy.
Targeting Cancer Stem Cells Targeting Cancer Stem Cells
November 3, 2011 |
Cancer stem cells (CSCs) have been identified in several types of cancer, and may play a role in tumorigenic growth, metastasis, and therapeutic resistance. New anticancer therapeutics are being developed that will inhibit tumor growth and reduce tumor-initiating cell frequency, improving clinical cancer therapy. The development of new agents that block key CSC pathways will be described, as well as a novel assay for tracking CSCs in cell populations without the need to isolate them, and a CSC screening strategy for discovering therapeutic antibodies.




Publications, Reports, & Whitepapers
Biomarkers: Neurobiomarkers and Neurodiagnostics
Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, published by Insight Pharma Reports has a focus in biomarkers for neurodegenerative diseases and diagnostic applications in development.